BELVIN MARCIA 4
4 · CytomX Therapeutics, Inc. · Filed Mar 21, 2024
Insider Transaction Report
Form 4
BELVIN MARCIA
SVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-03-19$2.09/sh−12,795$26,684→ 168,579 total
Footnotes (2)
- [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.
- [F2]Includes 109,166 restricted stock units.